CARDIOMEMS HF SYSTEM

About the CardioMEMS HF System

The CardioMEMS™ HF System allows clinicians to monitor heart failure patients’ pulmonary artery (PA) pressure for proactive and actionable heart failure (HF) management and treatment. With early indications of worsening heart failure, you can remotely make adjustments to care to help slow the progression of heart failure, often before patients feel symptoms.

The CardioMEMS HF System is proven to:

• Aid physicians in preventing worsening heart failure¹ and lowering mortality rates²
• Significantly reduce heart failure hospitalizations^3,4
• Improve quality of life in New York Heart Association (NYHA) Class III patients hospitalized for heart failure in the previous 12 months⁵

Indications

The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous 12 months. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Contraindications

The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CARDIOMEMS HF SYSTEM CLINICAL EVIDENCE

Multiple clinical trials have evaluated the safety and effectiveness of the CardioMEMS HF System. For a deep dive into the clinical data, visit the Clinical Evidence and Journal Article information.

Highlights from recent real-world data

REIMBURSEMENT & CODING HIGHLIGHTS

Our full reimbursement resource documents provide information about coverage, coding and payment, denied claims and supporting documentation for the CardioMEMS HF System.

CardioMEMS HF System Coding Guide

This guide includes information regarding coverage, coding and reimbursement.

CardioMEMS HF System FAQ Guide

For the full resource list, visit Reimbursement & Coding for the CardioMEMS HF System.

Indications, Safety and Warnings

References

1. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
   
2. Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
   
3. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
   
4. Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357-65.
   
5. Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. http://dx.doi.org/10.1016/S0140-6736(11)60101-3
   
6. Shavelle D. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. Advance online publication. https://doi.org/10.1161/circheartfailure.119.006863